AU Patent

AU2017262943B2 — Stabilized glycopeptide antibiotic formulations

Assigned to Xellia Pharmaceuticals ApS · Expires 2020-05-14 · 6y expired

What this patent protects

Disclosed herein are liquid formulations of glycopeptide antibiotics or pharmaceutically acceptable salts thereof, wherein glycopeptide antibiotic is selected from Vancomycin, Telavancin, Oritavancin, Teicoplanin and Dalbavancin. Said formulations are suitable as infusion solutio…

USPTO Abstract

Disclosed herein are liquid formulations of glycopeptide antibiotics or pharmaceutically acceptable salts thereof, wherein glycopeptide antibiotic is selected from Vancomycin, Telavancin, Oritavancin, Teicoplanin and Dalbavancin. Said formulations are suitable as infusion solutions or as a concentrate for making infusion solutions.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017262943B2
Jurisdiction
AU
Classification
—
Expires
2020-05-14
Drug substance claim
No
Drug product claim
No
Assignee
Xellia Pharmaceuticals ApS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.